logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
VIR
Vir Biotechnology, Inc.
10.60
2 x 7.75
2 x 13.41
bid
ask
-
0.32
2.93%
2 @ 04:00 PM
10.50 -0.10 (0.94%)
Ytd75.79%
1y104.63%
10.44
day range
11.00
4.82
52 week range
11.94
Open10.92Prev Close10.92Low10.44High11.00Mkt Cap1.79B
Vol7.02MAvg Vol1.93MEPS-1.77P/EN/AForward P/E-4.26
Beta1.63Short Ratio12.64Inst. Own84.20%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0450-d Avg9.84200-d Avg8.801yr Est20.78

VIR News

Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR
defenseworld.net
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR

Engineers Gate Manager LP trimmed its stake in Vir Biotechnology, Inc. (NASDAQ: VIR) by 48.7% during

Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)
defenseworld.net
Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and Crescent Biopharma (NASDAQ: CBIO - Get Free Re

Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR
defenseworld.net
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR

Bank of New York Mellon Corp bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
businesswire.com
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne

Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR
defenseworld.net
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR

Algert Global LLC grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ: VIR) by 64.6% duri

ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR
defenseworld.net
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR

ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
seekingalpha.com
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Q2 Earnings Call Highlights
defenseworld.net
Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology (NASDAQ: VIR) reported second-quarter 2026 results alongside updates on its chroni

Vir Biotechnology Q2 Earnings Call Highlights
marketbeat.com
Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
zacks.com
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
businesswire.com
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate up

Vir Biotechnology Announces Chief Financial Officer Transition
gurufocus.com
Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and

Vir Biotechnology Announces Chief Financial Officer Transition
businesswire.com
Vir Biotechnology Announces Chief Financial Officer Transition

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sab

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
businesswire.com
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will h

Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead
seekingalpha.com
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead

Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIP

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
businesswire.com
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointmen

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
businesswire.com
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company wi

Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
fool.com
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborati

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
fool.com
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging part

Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
seekingalpha.com
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity

Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline,